论文部分内容阅读
目的检测多药耐药基因MDR1(Multidrug Resistance Gene 1)在卵巢癌患者卵巢癌组织、外周血白细胞和腹水癌细胞中的表达情况,探讨三者间的关系,更好的指导临床。方法标本取自2008年10月-2011年10月在河北联合大学附属医院就诊且手术的32例经临床及病理学证实为卵巢癌初治患者。年龄31~67岁之间,术中留取卵巢癌组织及其外周血各32例,腹水28例(4例患者无腹水)应用RT-PCR法检测卵巢癌组织及外周血和腹水中的MDR1的表达情况,并探讨其三者之间的相关性。结果 32例卵巢癌患者卵巢癌组织、外周血白细胞及腹水28例癌细胞中MDR1表达阳性率分别为(31.2%、21.9%、28.6%),3种标本间差异无统计学意义(P>0.05)。3种标本间2两检测,经统计学处理,差异无统计学意义(P>0.05),且两种标本间MDR1表达具有一致性。结论初治卵巢癌中卵巢癌组织与外周血白细胞及腹水癌细胞中的MDR1表达具有一致性。
Objective To detect the expression of multidrug resistance gene 1 (MDR1) in ovarian cancer tissues, peripheral blood leucocytes and ascitic carcinoma cells, and to explore the relationship among them and to guide the clinical practice. Methods From October 2008 to October 2011 in our hospital, Hebei Union University Hospital, surgical specimens of 32 patients clinically and pathologically confirmed as initial treatment of ovarian cancer patients. Between the ages of 31 and 67, 32 cases of ovarian cancer tissue and peripheral blood were collected and 28 cases of ascites (4 cases without ascites). RT-PCR was used to detect the expression of MDR1 in ovarian cancer tissues, ascites and ascites Of the expression, and explore the correlation between the three. Results The positive rates of MDR1 in ovarian cancer tissue, peripheral blood leukocytes and ascites in 32 cases of ovarian cancer patients were 31.2%, 21.9%, 28.6%, respectively. There were no significant differences among the 3 specimens (P> 0.05 ). There was no significant difference between the two groups (P> 0.05). The MDR1 expression was consistent between the two specimens. Conclusions The expression of MDR1 in ovarian cancer tissues and peripheral blood leucocytes and ascitic carcinoma cells in newly diagnosed ovarian cancer is consistent.